Fierce Pharma September 18, 2024
With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a potential blockbuster in tow.
Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced Wednesday. Under the terms of the deal—which is expected to close in the fourth quarter—Organon will dish out an upfront payment of $175 million.
Organon will also furnish Dermavant with a $75 million milestone payment contingent upon Vtama’s approval in atopic dermatitis (eczema), which is also expected in the last three months of 2024.
Another $950 million is on the table for Dermavant based on the achievement of certain commercial milestones, the companies said. Plus, Organon will pay Dermavent shareholders tiered...
Today's Sponsors
Today's Sponsor